Compare Abbott Laboratories (ABT) vs SpaceX (SPCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs SpaceX — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while SpaceX trades at $149.5 (market cap $1.97T). The key difference: SpaceX is far larger — about 11.8× Abbott Laboratories's market cap, and Abbott Laboratories pays a 2.63% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| ABT | SPCX | |
|---|---|---|
Market Cap | $166.94B | $1.97T |
Sector | Health | Technology |
52-Week High | $136.62 | $202.09 |
52-Week Low | $82.57 | $135.00 |
Enterprise Value | $193.69B | $1.98T |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SPCX trades at $160.42, down 0.86% amid its Nasdaq-100 debut. Technical indicators are neutral, with support at $154 and resistance at $167. The company reported 2025 revenue of $18.67B but a net loss of $4.94B, with negative profit margins and high valuation multiples like P/S of 108.68. Recent news highlights inclusion in the Nasdaq-100 and analyst optimism, though earnings misses and cash burn from heavy investing raise concerns.
Outlook: Strong analyst consensus (100% buy, $240.80 target) reflects long-term growth faith in SpaceX's space economy role. However, persistent losses, high valuations, and execution risks in capital-intensive projects present significant downside. Investors face volatility from earnings uncertainty and competitive pressures, balancing speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
